-

Mark Clements of Glooko Recognized on Becker's Healthcare's 2026 'Great leaders in healthcare' List

Recognition highlights leadership in clinically grounded diabetes innovation and evidence-driven care

original

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that Mark Clements, M.D., Ph.D., its Chief Medical and Strategy Officer, has been recognized by Becker's Healthcare as one of its 2026 'Great leaders in healthcare.'

"Dr. Clements helps translate complex clinical and data science insights into clear direction for our teams and keeps our work focused on meaningful impact for providers, health systems, and people living with diabetes."

Share

The Becker's recognition honors leaders whose work is helping shape the future of healthcare. Dr. Clements was recognized for the impact of his leadership in diabetes care, including his ability to bridge clinical practice, research, and digital innovation.

At Glooko, Dr. Clements helps guide the company's clinical vision and strategy, ensuring that innovation remains grounded in evidence, aligned with clinical realities, and focused on better experiences and outcomes for individuals with diabetes and clinical teams. His leadership has helped strengthen Glooko's clinical rigor, shape research collaboration, and advance a product strategy informed by science and real-world care needs.

"Dr. Clements brings deep credibility across medicine, research, and healthcare technology," said Mike Alvarez, Chief Executive Officer of Glooko. "He helps translate complex clinical and data science insights into clear direction for our teams and keeps our work focused on meaningful impact for providers, health systems, and people living with diabetes. We are proud to see him recognized by Becker's Healthcare."

In addition to his work at Glooko, Dr. Clements is a respected leader in diabetes research and education. His contributions have helped advance more data-informed approaches to disease management and have improved care for people living with diabetes, including youth and underserved populations.

The full Becker's Healthcare 2026 'Great leaders in healthcare' list is available here.

About Glooko

Glooko is a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum. Glooko is uniquely positioned to be the enterprise partner of choice for healthcare providers seeking to reduce glycemic risk, improve safety, and support overburdened clinical teams with coordinated expertise across both outpatient and inpatient care settings.

Contacts

Media contact:
Julia Fuller
Vice President, Corporate Communications & Brand
pr@glooko.com

Industry:

Glooko, Inc.

Release Versions
English

Contacts

Media contact:
Julia Fuller
Vice President, Corporate Communications & Brand
pr@glooko.com

Social Media Profiles
Glooko Facebook
Glooko LinkedIn
Glooko X
More News From Glooko, Inc.

Glooko Introduces the First and Only Pump Settings EHR Integration to Bring Insulin Pump Data Directly Into Clinical Workflows

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the launch of its Insulin Pump Settings Electronic Health Record (EHR) Integration, a new and first-of-its-kind capability in its latest software release that visualizes critical insulin pump configuration data directly into the clinical workflow. For clinics caring for...

Glooko Announces FDA 510(k) Clearance for EndoTool IV Cloud

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp...

Glooko and mylife Diabetes Care Expand Diabetes Data Management Partnership

GOTHENBURG, Sweden & BURGDORF, Switzerland--(BUSINESS WIRE)--Glooko, Inc. and mylife Diabetes Care today announced an agreement to further expand their partnership, under which Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products. This next step builds on the strong, well-established collaboration between the two companies, ensuring continuity in the way healthcare professionals and patients access data from mylife products, including mylife Loop, an...
Back to Newsroom